Performance. Defined.

InVitria Blog | Cell Culture and Biotech Manufacturing Insights

Stabilizing Virus with Albumin to Improve Yield

Posted By Randy Alfano Ph.D. on 10/22/19 11:02 AM

Workflow Summary:

Expand virus-producing cells to desired confluency. RemoveNew call-to-action growth medium and add the desired virus to be expanded (virus or plasmid DNA). Add Exbumin (Product Number: 777HSA097S) to the expression media and allow virus to propagate. Harvest culture and determine virus titer by preferred method.

Here, a general protocol is described for the addition of recombinant albumin, in the form of the product Exbumin, to virus production systems to stabilize infectious particles and thereby maximize viral yield.

 

Read More

Controlling Impurities in Cell Culture Media

Posted By Genetic Engineering & Biotechnology News on 9/16/19 6:12 AM

Originally Published by GEN, written by K. John Morrow Jr., PhD

From its initial development back in the 1950s, cell culture media development has been plagued by impurities, often present in small quantities, difficult to characterize, and trace back to their origins. Classically, culture media have required the addition of animal serum, which serves a nutritional function, but also may absorb and bind up trace impurities that may be inhibitory to cell growth.

However, with higher purity reagents and better characterization it has been possible to concoct a large range of different serum-free media, of special value when proteins synthesized by engineered cells need to be purified from their resident media. This means that it is even more critical to trace minor impurities in culture media.

Read More

Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells

Posted By Marcus Curl on 6/27/19 8:29 PM

rhLIF App Note #1 Download CTA ButtonWorkflow Summary:

Applying neural stem cells (NSC) as a cell therapy has created new hope for the treatment of various neural degenerative diseases as well as the reversal of neural damage once thought to be irreparable. Currently, clinical trials are being performed to evaluate NSC for the treatment of stroke, Parkinson’s disease, spinal cord injuries, and many other indications [1]. As new potential applications emerge and new clinical trials begin, the need for scalable and safe sources of the foundational cell culture materials becomes essential to the future of this technology. The ability to quickly and reliably expand neural NSCs in culture has therefore been essential to the exploration of these novel, cell-based therapeutic approaches. The goal of this application note is to provide step-by-step instructions for using InVitria’s recombinant hLIF in the efficient, safe, and scalable expansion of NSC in culture.

Read More

Reconstitution of Cellastim S for Cell-Culture Applications

Posted By Marcus Curl on 6/18/19 8:53 AM

Workflow Summary:Cellastim S Reconstitution Application Note #2 Download CTA Button

Human serum albumin (HSA) has been identified as a powerful tool for the expansion of many cell types in vitro [1]. HSA is a multifaceted protein capable of binding many different types of molecules [2]. HSA therefore plays diverse roles in cell biology, acting as an antioxidant to improve health of cells by binding to reactive oxygen species, as an energy-delivery system by chaperoning fatty acids in the bloodstream, and as a mediator for solubilization and stabilization of metal ions required for cellular processes [2,3]. These functions make HSA supplementation of cell culture media an integral step in facilitating cell growth and expansion in vitro, especially when removing serum or blood-derived proteins for use in clinical manufacturing. Using Cellastim S as a recombinant and scalable source of albumin in cell culture is an enabling tool for large-scale manufacture of cell-based and gene therapies. It is the goal of this app note to provide a step-by-step overview for preparing Cellastim S for use as a stock liquid solution for in vitro cell culture applications.

Read More

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Posted By Scott Deeter on 6/10/19 2:12 PM

Last week was the annual Biotechnology Industry Organization (BIO) annual convention in Philadelphia where medical innovations were abundant and showed remarkable promise. More than 17,000 delegates representing government, academia, and non-profit research institutes joined more than 4,000 companies in the City of Brotherly Love. The delegates share a common commitment to improve the quality and longevity of life through development of innovative new technologies, many of which are being commercialized at a pace not seen before. From vaccines to cell therapies and gene therapies, new products are promising substantial improvements to human health.

Read More